Vaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson Acquires 20,000 Shares

Vaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was bought at an average cost of $0.68 per share, for a total transaction of $13,600.00. Following the completion of the transaction, the director now directly owns 78,125 shares of the company’s stock, valued at approximately $53,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Vaxart Stock Up 5.2 %

NASDAQ:VXRT opened at $0.72 on Friday. The firm’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.90. Vaxart, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $1.54.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $2.18 million during the quarter. Vaxart had a negative return on equity of 121.06% and a negative net margin of 920.00%. On average, analysts forecast that Vaxart, Inc. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Vaxart

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC acquired a new position in shares of Vaxart in the 1st quarter valued at about $32,000. PFG Investments LLC purchased a new position in Vaxart in the first quarter valued at approximately $38,000. Tidal Investments LLC acquired a new position in Vaxart during the first quarter valued at approximately $56,000. Beacon Capital Management LLC lifted its position in Vaxart by 369.9% during the fourth quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 40,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Vaxart by 19.9% in the first quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock worth $10,984,000 after acquiring an additional 1,404,391 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.